Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

548.51 +8.46 (+1.57%)
Streaming Delayed Price Updated: 9:42 AM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
Earnings Outlook For United Therapeutics ↗
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that United... 
Via Benzinga
News headline image
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
From United Therapeutics Corporation
Via Business Wire
News headline image
7 Best Pharmaceutical Stocks to Buy Now ↗
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
News headline image
Swing Trading Stock Watchlist For The Week Of July 11 And Beyond ↗
The stock market's health is improving, but a likely bottom has not been confirmed yet. That means I’m buying some stocks (swing trades), but I'm not loading up yet. Let's see what I'm looking at. 
Via Talk Markets
News headline image
Expert Ratings for United Therapeutics ↗
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings: 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts Coming in July ↗
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
News headline image
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market ↗
Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions. 
Via Talk Markets
News headline image
Corcept Stock Near Buy Point; Strength Rating Jumps To 91 ↗
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year. 
Via Investor's Business Daily
News headline image
Will Investors Notice Exciting Sign On United Therapeutics's Chart? ↗
If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
News headline image
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
Short Volatility Alert: United Therapeutics Corporation ↗
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The... 
Via Benzinga
News headline image
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot' ↗
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
United Therapeutics Announces FDA Approval of Tyvaso DPI™
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics's Return on Invested Capital Insights ↗
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million... 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts for May ↗
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Recap: United Therapeutics Q1 Earnings ↗
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
Earnings Scheduled For May 4, 2022 ↗
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga
News headline image
Earnings Outlook For United Therapeutics ↗
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United... 
Via Benzinga
News headline image
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET ↗
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this... 
Via Benzinga
News headline image
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
From United Therapeutics Corporation
Via Business Wire
News headline image
First Human With Pig Heart Transplant Dies: Reuters ↗
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading. 
Via Benzinga
News headline image
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world 
Via Newswire.com
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.